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with a New Bioactive Prosthetic Graft:
Early and Late ResultsWalter Dorigo, Francesca Di Carlo, Nicola Troisi, Giovanni Pratesi,
Alessandro Alessi Innocenti, Raffaele Pulli, and Carlo Pratesi, Florence, ItalyThe aim of the study was to evaluate the immediate and long-term results of femoropopliteal
bypasses performed with a new bioactive heparin-treated expanded polytetrafluoroethylene
(ePTFE) graft in a single-center experience. From March 2002 to April 2006, 51 patients under-
went lower limb revascularization with a new bioactive ePTFE prosthetic graft with covalent end-
point attachment of heparin to the graft surface. Data concerning preoperative assessment, intra-
operative strategy, drug administration, and follow-up surveillance program were prospectively
collected in a dedicated database; early results were analyzed in terms of graft patency, ampu-
tation rate, and deaths. Follow-up consisted of clinical and duplex scan examination at 1, 6, and
12 months and yearly thereafter. Midterm results in terms of primary and secondary patency,
limb salvage, and survival were analyzed. Patients were predominantly male (35 patients,
71%), with a mean age of 71 years (SD ¼ 9.05). Indications for surgical revascularization
were critical limb ischemia in 36 patients and severe intermittent claudication in 15 patients. In-
terventions were performed for occlusion of a native vessel in 35 cases, whereas 12 patients had
late thrombosis of a femoropopliteal bypass; the remaining four patients were operated on for an
occluded popliteal artery aneurysm. Intervention consisted of below-knee bypass in 34 patients,
while the other 17 had an above-knee revascularization. No perioperative deaths occurred. Cu-
mulative 30-day graft patency was 88%, with an amputation rate of 4% (two cases). Results were
similar in above- and below-knee revascularizatons. Mean duration of follow-up was 18 months
(SD ¼ 7). Cumulative estimated 24-month survival and primary patency rates were 97% and
80.2%, respectively; the corresponding limb salvage rate was 85.7%. Long-term results did
not significantly differ in above- and below-knee revascularizatons. In our experience, the use
of a modified ePTFE graft with covalent end-point linkage of heparin molecules on the graft sur-
face provides good early and midterm results, with low rates of graft thrombosis and amputation.INTRODUCTION
Early and late graft occlusion is the main unsolved
problem in lower limb revascularizations, despite at-
tempts to develop an ‘‘ideal’’ small-diameter pro-
sthetic vascular graft that is highly biocompatible
and thrombosis-resistant.t of Vascular Surgery, University of Florence, Florence,
ence to: Raffaele Pulli, MD, Department of Vascular
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ne: December 18, 2007Several studies and international consensus1
have demonstrated that vein has better long-term
patency than prosthetic grafts in the infrainguinal
region. Prosthetic materials, particularly polytetra-
fluoroethylene (PTFE), provide near equivalent
results in above-knee sites, while in below-knee
revascularizations2 mid- and long-term results of
PTFE grafts are still poor, with<50% 2-year primary
patency rates.
In low-flow and high-resistance situations, no syn-
thetic graft has shown enough resistance to thrombo-
sis to enable routine adoption in more demanding
clinical applications such as below-knee bypass, par-
ticulary when autologous veins are not suitable.3
If one excludes technical errors and the progres-
sion of atherosclerosis in inflow and outflow vessels,79
Table I. Comorbidities and common risk factors
for atherosclerosis
Arterial hypertension 39 (76.5%)
Smoking 37 (72.5%)
Diabetes 13 (25.5%)
Hyperlipemia 33 (64.7%)
Coronary artery disease 22 (43.1%)
80 Dorigo et al. Annals of Vascular Surgerythe main cause of early graft thrombosis is an intrin-
sic graft thrombogenicity, whereas anastomotic
myointimal hyperplasia in most cases leads to late
failure of the revascularization.4
As a consequence, the reduction of graft throm-
bogenicity and the inhibition of neointimal forma-
tion seems to represent a logical strategy to
prevent early and late graft thrombosis.
In recent years, several modified prosthetic vas-
cular grafts have been developed and studied, with
particular chemical, physical, and mechanical pro-
perties aimed at improving intrinsic thromboresis-
tance; particularly, the use of heparin-bonded
grafts has been proposed as an alternative to autolo-
gous vein to reduce both early thrombotic risk and
late myointimal hyperplasia development, due to
anti-inflammatory properties of this antithrombotic
drug.5
Recently, a new bioactive PTFE graft with cova-
lent end-point attachment of heparin to the graft
surface, enabling maintenance of functional hepa-
rin bioactivity, has been developed; and its effective-
ness in terms of improvement of early graft patency
has been demonstrated in an experimental study;6
recently, data from a multicenter study7 demon-
strated promising results in terms of early patency
and limb salvage, even if follow-up was limited to
1 year. Moreover, we reported in a previous experi-
ence8 initial satisfactory results with this modified
graft in below-knee revascularizations compared
with those obtained with standard expanded PTFE
(ePTFE).
The aim of this study was to retrospectively
evaluate the immediate and long-term results of
above- and below-knee femoropopliteal bypasses
performed with this new bioactive heparin-treated
ePTFE graft in our experience.MATERIALS AND METHODS
From March 2002 to April 2006, a new bioactive
prosthetic graft (Propaten Gore-Tex; W. L. Gore,
Flagstaff, AZ), which consists of an ePTFE prosthetic
graft with covalent end-point attachment of heparin
to the graft surface, was implanted in 51 patients un-
dergoing lower limb revascularization; the covalent
end-point linkages maintain the catalytic bioactivity
of the antithrombin sites of the bound heparin.9
Data concerning these patients were prospec-
tively collected in a dedicated database containing
main pre-, intra-, and postoperative parameters.
Early results were analyzed in terms of graft
patency, amputation rate, and deaths. Differences
in subgroups were assessed by the c2 test. Clinicaland ultrasonographic follow-up was performed at
1, 6, and 12 months and then once a year. All studies
were performed using the Acuson Sequoia 512
Ultrasound System (Acuson, Mountain View, CA).
An 8L5 linear array probe with an operating
frequency of 8.0-5.0 MHz was used in all cases.
Long-term results were analyzed by Kaplan-
Meier curves, and differences in subgroups were
assessed by the log-rank test.RESULTS
Patients were predominantly males (35 patients,
71%), with a mean age of 71 years (standard devia-
tion [SD] ¼ 9.05). Comorbidities and main risk fac-
tors for atherosclerosis are summarized in Table I.
Indications for surgical intervention were the pre-
sence of critical limb ischemia in 36 patients (Ruth-
erford class 4 in 19 patients, class 5 in 14 patients,
and class 6 in the remaining three); in 15 patients se-
vere intermittent claudication (IIb degree according
to the Fontaine classification and Rutherford class 3)
was present (Table II). Interventions were per-
formed in 35 cases for occlusion of a native vessel
and in 12 patients for an occluded femoropopliteal
bypass; four patients were operated on for an
occluded popliteal artery aneurysm. In all patients
undergoing below-knee bypass, preoperative du-
plex scanning of superficial veins of the limbs was
performed, showing unsuitable autologous saphe-
nous vein due to small diameter (<3 mm), valvular
incompetence with varicose veins, previous phlebi-
tis, and previous surgical harvesting. Mean preoper-
ative ankle-brachial index in the affected limb was
0.42 (SD ¼ 18). All patients were preoperatively
treated with antiplatelet drugs. Intervention con-
sisted of a below-knee bypass in 34 patients, and
the remaining 17 had an above-knee revasculariza-
tion. Distal targeted vessels are reported in Table II.
Associated interventions were performed in 26 pa-
tients and consisted of proximal or distal patching
in five patients, endovascular treatment of inflow
or outflow vessel disease in four patients, and distal
surgical thrombectomy in 17 patients. Intra-
operative stop-flow thrombolysis10,11 was used in
14 patients.
Table II. Clinical features (Fontaine and
Rutherford classifications), run-off score, kind of
intervention, and site of distal anastomosis
n (%)
Severe claudication (IIB) 15 (29.5%)
Critical ischemia
Rest pain 19 (37.3%)
Ulcers 17 (33.3%)
Rutherford class 3 15 (29.5%)
Rutherford class 4 19 (37.3%)
Rutherford class 5 14 (27.4%)
Rutherford class 6 3 (5.8%)
Run-off score
0-1 vessels 34 (66.7%)
2-3 vessels 17 (33.3%)
Redo surgery 12 (23.5%)
Distal anastomosis
Above-knee popliteal artery 17 (33.3%)
Below-knee popliteal artery 29 (56.7%)
Tibioperoneal trunk 5 (10%)
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Fig. 1. Cumulative primary patency during follow-up.
Vol. 22, No. 1, 2008 ePTFE graft to manage obstructive chronic peripheral disease 81All patients had intraoperative administration of
2,000 IU of i.v. heparin at arterial clamping; in all
patients the postoperative drug protocol consisted
of i.v. heparin administration (800-1,000 IU/hr) fol-
lowed by oral anticoagulants in patients who had
undergone below-knee bypass, to maintain the in-
ternational normalized ratio (INR) range 2.0-3.0,12
and double antiplatelet therapy in patients with
above-knee revascularization.
There were neither perioperative deaths nor
severe bleeding; early (<30 days) graft thrombosis
occurred in six patients (cumulative graft patency
was 88%). All these patients were immediately re-
operated on, and the intervention was successful
in four cases. In two cases surgical revascularization
was impossible and major amputation was per-
formed, with a 30-day amputation rate of 4%.
Results in terms of thrombosis and amputation rates
were similar in above- and below-knee revasculari-
zations; in fact, there were one (5.8%) thrombosis
in the above-knee group and five (14.5%, p ¼ non-
significant [n.s.]) in the below-knee group and no
amputations in the above-knee group and two
(5.5%, p ¼ n.s.) in the below-knee group.
Mean duration of follow-up was 18 months
(range 1-60); all patiens had at least one postopera-
tive clinical and ultrasonographic examination.
During follow-up, one death, seven new graft
thomboses, and four amputations occurred.
All graft thromboses during follow-up occurred
in patients without significant lesions detected at
follow-up duplex scanning examinations. Only
two patients showed 60% stenoses at distalanastomoses; one patient had a <60% stenosis at
distal anastomosis, and in three cases no significant
lesions were found. The remaining patient had graft
thrombosis due to occlusion of ipsilateral external il-
iac and common femoral arteries.
There were five reinterventions, in all cases due
to graft thrombosis. In these patients intraoperative
findings showed distal intimal hyperplasia causing
graft occlusion in all but one patient, who had
progression of atherosclerosis in his inflow vessels.
In two cases the graft occluded without signs and
symptoms of limb ischemia and the patients were
medically treated. Cumulative estimated 24-month
survival as well as primary and secondary patency
rates were 97%, 80.2%, and 81.2% (Figs. 1 and
2), respectively. The corresponding limb savage
rate was 85.7% (Fig. 3).
Follow-up results were similar in above- and
below-knee revascularizations in terms of primary
patency (78.6% and 80.6%, respectively; p ¼ n.s.;
log rank 4.1), secondary patency (80.6% and
81.3%, respectively; p ¼ n.s.; log rank 1.1), and
limb savage (90.1% and 83.6%, respectively; p ¼
n.s.; log rank 10.5). Primary patency and limb
savage rates were not affected by the need for
reintervention, the level of revascularization, and
preoperative clinical status, analyzed with both the
Fontaine and Rutherford classifications.
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Fig. 2. Secondary patency during follow-up.
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Fig. 3. Cumulative limb salvage.
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The main problem in lower limb revascularization is
the not negligible rate of early and late failure,
defined as the impossibility of maintaining graft
patency, away from clinical manifestations of graft
occlusion.
Data from meta-analysis and main mono- and
multicentric series showed that the rate of graft
failure, independently from preoperative clinical
status, kind of graft, and site of distal anastomosis,
ranges 25-35% at 2 years.13,14 Most graft occlusions
occur during the early postoperative period: when
considering synthetic vascular graft, the rate of oc-
clusions is 53 cases/1,000 patients/month in the first
3 postoperative months; the corresponding figures
at 6 and 12 months are 21 cases/1,000 patients/
month, whereas in following years the rate de-
creases to 10 cases/1,000 patients/month.15
Starting from these data, several studies have
tried to identify the ideal vascular graft for peri-
pheral revascularizations that is highly biocompati-
ble and thrombosis-resistant.
Whereas the superiority of autologous veins
over prosthetic grafts has been clearly demon-
strated in below-knee revascularizations,16 there
is no consensus concerning the best synthetic vas-
cular graft to be used when autologous veins arenot suitable. In these situations, several authors
have proposed the use of distal artery adjunct pro-
cedures, such as vein interposition of cuffs; how-
ever, results, even if promising, are limited by the
small number of patients and the absence of com-
parison trials.1
For these reasons, in recent years, several at-
tempts have been made to develop new prosthetic
materials with increased intrinsic thrombosis resis-
tance due to modifications of chemical and physical
graft properties.
Particularly, the use of heparin bonded to bio-
material surfaces17 has been proposed both to re-
duce graft thrombogenicity, which represents the
main cause of early graft failure, and to inhibit
the formation of myointimal hyperplasia at anas-
tomotic sites, which usually leads to late graft
occlusion.
Heparin not only provides a specific antithrom-
botic effect, due to its interaction with the throm-
bineantithrombin system, but also shows intrinsic
anti-inflammatory properties and can potentially
lead in vivo to inhibition of the proliferation and
migration of smooth muscle cells, which represents
the main pathophysiological mechanism of neointi-
mal hyperplasia.18
Several studies were published in the last decade
concerning the use of heparin-coated synthetic
  Time       Status       Cumulative     Standard     Cumulative      Number 
                           Survival       Error         Events       Remaining 
     ,00          ,00                                          1            50 
     ,00          ,00                                          2            49 
     ,00          ,00                                          3            48 
     ,00          ,00        ,9216          ,0376              4            47 
     ,00         1,00                                          4            46 
     ,00         1,00                                          4            45 
    1,00         1,00                                          4            44 
    3,00         1,00                                          4            43 
    3,00         1,00                                          4            42 
    3,00         1,00                                          4            41 
    3,00         1,00                                          4            40 
    3,00         1,00                                          4            39 
    5,00         1,00                                          4            38 
    6,00         1,00                                          4            37 
    6,00         1,00                                          4            36 
    6,00         1,00                                          4            35 
    6,00         1,00                                          4            34 
    6,00         1,00                                          4            33 
    7,00         1,00                                          4            32 
    9,00         1,00                                          4            31 
   12,00         1,00                                          4            30 
   12,00         1,00                                          4            29 
   12,00         1,00                                          4            28 
   12,00         1,00                                          4            27 
   15,00          ,00        ,8874          ,0494              5            26 
   15,00         1,00                                          5            25 
   15,00         1,00                                          5            24 
   15,00         1,00                                          5            23 
   15,00         1,00                                          5            22 
   15,00         1,00                                          5            21 
   18,00          ,00                                          6            20 
   18,00          ,00        ,8029          ,0723              7            19 
   18,00         1,00                                          7            18 
   24,00         1,00                                          7            17 
   24,00         1,00                                          7            16 
   24,00         1,00                                          7            15 
   24,00         1,00                                          7            14 
   24,00         1,00                                          7            13 
   24,00         1,00                                          7            12 
   26,00          ,00        ,7360          ,0922              8            11 
   26,00         1,00                                          8            10 
   28,00          ,00                                          9             9 
   28,00          ,00        ,5888          ,1188             10             8 
   28,00         1,00                                         10             7 
   30,00          ,00        ,5047          ,1282             11             6 
   30,00         1,00                                         11             5 
   32,00          ,00        ,4038          ,1366             12             4 
   36,00          ,00        ,3028          ,1347             13             3 
   36,00         1,00                                         13             2 
   36,00         1,00                                         13             1 
   60,00         1,00                                         13             0 
Life-table for figure 1
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with great expectations but often conflicting results.
Particularly, there are few data in the litera-
ture5,17,24 concerning the results of heparin-bonded
ePTFE grafts.
The modified ePTFE graft we studied could re-
present an evolution in the development of bioac-
tive synthetic vascular grafts; in fact, heparin
does not simply cover the graft surface, as in
most bonded grafts, but it is immobilized on the
graft, producing a surface microstructure havingstable, covalently bound heparin. The covalent
end-point linkages maintain the catalytic bioactivi-
ty on the antithrombin sites of the bound hepa-
rin.9 This peculiarity should lead to uniform
surface heparinization and sustained in vivo hepa-
rin bioactivity; in other words, heparin would
persist on the graft surface for a longer time, in-
creasing its antithrombotic and anti-inflammatory
properties.
A recent experimental study conducted on a
canine carotid interposition model6 demonstrated
  Time       Status       Cumulative     Standard     Cumulative      Number 
                           Survival       Error         Events       Remaining 
     ,00          ,00                                          1            50 
     ,00          ,00        ,9608          ,0272              2            49 
    1,00         1,00                                          2            48 
    3,00         1,00                                          2            47 
    3,00         1,00                                          2            46 
    3,00         1,00                                          2            45 
    3,00         1,00                                          2            44 
    3,00         1,00                                          2            43 
    5,00         1,00                                          2            42 
    6,00         1,00                                          2            41 
    6,00         1,00                                          2            40 
    6,00         1,00                                          2            39 
    6,00         1,00                                          2            38 
    6,00         1,00                                          2            37 
    7,00         1,00                                          2            36 
    9,00         1,00                                          2            35 
   12,00         1,00                                          2            34 
   12,00         1,00                                          2            33 
   12,00         1,00                                          2            32 
   12,00         1,00                                          2            31 
   12,00         1,00                                          2            30 
   15,00          ,00        ,9288          ,0410              3            29 
   15,00         1,00                                          3            28 
   15,00         1,00                                          3            27 
   15,00         1,00                                          3            26 
   15,00         1,00                                          3            25 
   15,00         1,00                                          3            24 
   18,00          ,00                                          4            23 
   18,00          ,00                                          5            22 
   18,00          ,00        ,8127          ,0722              6            21 
   18,00         1,00                                          6            20 
   18,00         1,00                                          6            19 
   18,00         1,00                                          6            18 
   24,00         1,00                                          6            17 
   24,00         1,00                                          6            16 
   24,00         1,00                                          6            15 
   24,00         1,00                                          6            14 
   24,00         1,00                                          6            13 
   24,00         1,00                                          6            12 
   26,00         1,00                                          6            11 
   26,00         1,00                                          6            10 
   28,00          ,00                                          7             9 
   28,00          ,00        ,6501          ,1179              8             8 
   28,00         1,00                                          8             7 
   30,00         1,00                                          8             6 
   30,00         1,00                                          8             5 
   36,00         1,00                                          8             4 
   36,00         1,00                                          8             3 
   36,00         1,00                                          8             2 
   48,00          ,00        ,3251          ,2373              9             1 
   60,00         1,00                                          9             0 
Life-table for figure 2
84 Dorigo et al. Annals of Vascular Surgerythat this modified bioactive ePTFE graft improved
patency compared to untreated control ePTFE
grafts; the patency difference, which was apparent
early in the postimplant period and was sustained
out to the 6-month end point, likely was attribut-
able to inhibition of thrombus formation conferred
by the immobilized heparin.
Our data confirm the results of experimental
studies showing a satisfactorily low rate of early
graft thrombosis; this study also confirms the fair
results described in our previous report,8 wherethis modified graft, used in below-knee revascular-
izations, was compared with autologous saphenous
vein and standard ePTFE and was found to have
poorer early and late results than autologous vein,
as expected, but significantly better early and mid-
term primary patency rates than standard ePTFE.
Also, Bosiers and colleagues7 reported good re-
sults in terms of early graft thrombosis and limb
salvage with the examined graft, with a 30-day
amputation rate of 4%, similar to the rate reported
in our series.
Life table analysis for limb salvage 
Time  Status 
Cumulative 
survival
Standard 
error. 
Cumulative 
events 
Number
remaining 
,000 1,00 . . 1 50
,000 1,00 ,961 ,027 2 49
1,000 ,00 . . 2 48
3,000 ,00 . . 2 47
3,000 ,00 . . 2 46
3,000 ,00 . . 2 45
3,000 ,00 . . 2 44
3,000 ,00 . . 2 43
5,000 ,00 . . 2 42
6,000 ,00 . . 2 41
6,000 ,00 . . 2 40
6,000 ,00 . . 2 39
6,000 ,00 . . 2 38
6,000 ,00 . . 2 37
7,000 ,00 . . 2 36
9,000 ,00 . . 2 35
12,000 ,00 . . 2 34
12,000 ,00 . . 2 33
12,000 ,00 . . 2 32
12,000 ,00 . . 2 31
12,000 ,00 . . 2 30
14,000 1,00 ,929 ,041 3 29
15,000 1,00 ,897 ,051 4 28
15,000 ,00 . . 4 27
15,000 ,00 . . 4 26
15,000 ,00 . . 4 25
15,000 ,00 . . 4 24
15,000 ,00 . . 4 23
18,000 1,00 ,857 ,062 5 22
18,000 ,00 . . 5 21
18,000 ,00 . . 5 20
18,000 ,00 . . 5 19
18,000 ,00 . . 5 18
24,000 ,00 . . 5 17
24,000 ,00 . . 5 16
24,000 ,00 . . 5 15
24,000 ,00 . . 5 14
24,000 ,00 . . 5 13
24,000 ,00 . . 5 12
26,000 ,00 . . 5 11
26,000 ,00 . . 5 10
28,000 1,00 ,772 ,098 6 9
28,000 ,00 . . 6 8
28,000 ,00 . . 6 7
30,000 ,00 . . 6 6
30,000 ,00 . . 6 5
32,000 ,00 . . 6 4
36,000 ,00 . . 6 3
36,000 ,00 . . 6 2
36,000 ,00 . . 6 1
60,000 ,00 . . 6 0
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86 Dorigo et al. Annals of Vascular SurgeryThis modified graft seems to affect surface throm-
botic processes, preventing graft thrombosis during
the initial high-risk period for thrombotic failure;
the mechanism of modulation of initial thrombus
accumulation has been explained with a reduced
platelet deposition on the graft surface, specifically
correlated with the immobilized high antithrom-
bin-affinity heparin fraction.25 Moreover, the sta-
ble, long-lasting covalent linkage between the
graft surface and heparin could influence not only
the extrinsic, platelet-mediated pathways but also
the intrinsic coagulation cascade. We did not find
a significant difference in terms of early graft throm-
bosis between above- and below-knee bypasses;
however, as expected, there was a higher percent-
age of graft thrombosis in below-knee revasculariza-
tions, and the difference, even if not statistically
relevant, is likely clinically relevant.
Results at 24 months were satisfactory in our ex-
perience, with 2-year patency and limb salvage
rates similar to those reported at 1-year follow-up
by Bosiers et al.;7 particularly in below-knee by-
passes, our 24-month 80% primary patency com-
pares favorably with the reported 24-month rate
of 48.2% in a recent meta-analysis on infraingui-
nal ePTFE grafts.2 It could be supposed that pro-
longed heparin bioactivity on the graft surface
can somehow influence the formation of anasto-
motic myointimal hyperplasia; particularly, long-
term patency rates may be significantly affected
by reduced thrombus accumulation in the first sev-
eral months after implant.5 It could be hypothe-
sized that sustained heparin activity may reduce
thrombus accumulation, thereby decreasing the
scaffold available for both midgraft and anasto-
motic remodeling events.CONCLUSIONS
The development of a synthetic vascular graft with
intrinsic high thromboresistance and low stimulus
to intimal hyperplasia formation in lower limb re-
vascularization is mandatory due to high failure
rates of below-knee bypasses when an adequate au-
tologous vein is not suitable. The modification of
chemical properties of prosthetic grafts and their
interaction with antithrombotic anti-inflammatory
drugs seems, at the moment, a promising strategy.
In our experience, the use of a new modified
ePTFE graft provides good early and midterm re-
sults, with low rates of graft thrombosis and amputa-
tion also in below-knee revascularizations, making
it a potential alternative to autologous saphenous
vein when it is absent, unsuitable, or of poor quality.REFERENCES
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